Stockscreener 앱 받기
1.775
9.20%
0.145
전일 마감가:
$1.63
열려 있는:
$1.71
하루 거래량:
1.84M
Relative Volume:
0.78
시가총액:
$44.85M
수익:
-
순이익/손실:
$-35.58M
주가수익비율:
-0.3927
EPS:
-4.52
순현금흐름:
$-42.82M
1주 성능:
+30.88%
1개월 성능:
+58.93%
6개월 성능:
+26.24%
1년 성능:
+4.09%
1일 변동 폭
$1.56
$1.83
1주일 범위
$1.31
$1.83
52주 변동 폭
$0.808
$2.50
Iterum Therapeutics Plc Stock (ITRM) Company Profile
명칭
Iterum Therapeutics Plc
전화
(872) 225-6077
주소
FITZWILLIAM COURT, 1ST FLOOR, DUBLIN 2
ITRM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| ITRM | 1.77 | 44.85M | 0 | -35.58M | -42.82M | -4.52 |
| VRTX | 450.15 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 744.74 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 597.26 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.93 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.42 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-05-28 | 업그레이드 | Gabelli & Co | Sell → Hold |
| 2021-03-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-06-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-01-21 | 다운그레이드 | Gabelli & Co | Buy → Sell |
| 2019-12-11 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-06-21 | 개시 | H.C. Wainwright | Buy |
모두보기
Iterum Therapeutics Plc 주식(ITRM)의 최신 뉴스
Iterum Therapeutics Regains Full Nasdaq Compliance - The Manila Times
Iterum Therapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Iterum Therapeutics plc (NASDAQ:ITRM) Q3 2024 Earnings Call Transcript - Insider Monkey
Iterum Therapeutics plc (ITRM) Quarterly 10-Q Report - Quartzy
Iterum Therapeutics PLC (ITRM) Q3 2024 Earnings Call Highlights: Strategic Moves Amid Financial Challenges - GuruFocus.com
Iterum Therapeutics PLC (ITRM) Q3 2024 Earnings Call Highlights: Strategic Moves Amid Financial ... - Yahoo Canada Finance
Iterum Therapeutics’ Strategic Advances with ORLYNVAH Approval - TipRanks
ARMISTICE CAPITAL, LLC Acquires New Stake in Iterum Therapeutics PLC - GuruFocus.com
Earnings Flash (ITRM) ITERUM THERAPEUTICS Reports Q3 Loss $-0.24 - Marketscreener.com
Iterum Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times
Iterum Therapeutics sees cash runway into 2025 - TipRanks
Iterum Therapeutics reports Q3 non-GAAP EPS (24c) vs. ($1.20) last year - TipRanks
Iterum's ORLYNVAH Gets FDA Nod; Q3 Shows $14.5M Cash Position Amid Wider Losses | ITRM Stock News - StockTitan
Iterum Therapeutics (ITRM) Scheduled to Post Earnings on Thursday - Defense World
Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024 - The Manila Times
Iterum Therapeutics defers $20 million FDA milestone payment By Investing.com - Investing.com Australia
Iterum Therapeutics defers $20 million FDA milestone payment - Investing.com India
Iterum Therapeutics : Financial Obligation Form 8 K - Marketscreener.com
500: Something went wrong - Investing.com UK
ITRMIterum Therapeutics plc Ordinary Share Latest Stock News & Market Updates - StockTitan
FDA Approves Oral Sulopenem (Orlynvah) for Uncomplicated Urinary Tract Infections - Contagionlive.com
Iterum Scores First Approval For Oral Penem Antibiotic - Citeline
Second Oral UTI Treatment Approved, But Still No Vaccine - Precision Vaccinations
Biotech Alert: Searches spiking for these stocks today - TipRanks
FDA Approval Of Orlynvah For Urinary Tract Infections Marks Milestone For Iterum, Paves Way For New Strategic Partnerships - Benzinga
FDA approves Iterum’s ORLYNVAH NDA for uUTI treatment - Pharmaceutical Technology
Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections - BioSpace
NaoTrac to Redefine Surgical Navigation Robotics at MEDICA 2024 - Lelezard
Iterum stock rallies 54% on FDA approval of Orlynvah for UTIs - MSN
Major Improvements In Iterum Therapeutics Plc (ITRM) Stock Need To Be Considered - Stocks Register
Iterum Therapeutics (ITRM) Scores FDA Approval for New UTI Drug ORLYNVAH™ - BP Journal
FDA approves new oral antibiotic ORLYNVAH for uUTIs By Investing.com - Investing.com Nigeria
Allovir (ALVR) Sees 5.06% Stock Price Surge Amid Mixed Analyst R - GuruFocus.com
Wall Street-Heavily Traded - WDRB
Iterum Therapeutics Shares Soar on FDA's Orlynvah Approval - Marketscreener.com
FDA approves new oral antibiotic ORLYNVAH for uUTIs - Investing.com India
Iterum Therapeutics Gains FDA Approval for ORLYNVAH - TipRanks
US FDA approves Iterum's treatment for urinary infection - Reuters.com
Iterum Therapeutics announces FDA approval of Orlynvah - TipRanks
Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections - The Manila Times
Week Ahead (Jul.26-30): INFI To Provide Update On Eganelisib Trials, Writing's On The Wall For ITRM? - RTTNews
Renaissance Technologies LLC Trims Stock Holdings in Iterum Therapeutics plc (NASDAQ:ITRM) - Defense World
Iterum Therapeutics to Present Data at IDWeek 2024 - StockTitan
Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit - The Manila Times
Iterum Therapeutics shareholders approve share issuance authority - Investing.com
Iterum Therapeutics shareholders approve share issuance authority By Investing.com - Investing.com Canada
Iterum Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com India
Iterum Therapeutics faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com UK
Iterum Therapeutics Plc (ITRM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):